ChartMill · Aug 25, 2026
Progyny (NASDAQ:PGNY): An Affordable Growth Stock With Strong Earnings and Reasonable Valuation
Progyny (PGNY) offers affordable growth: strong expected EPS growth of 28%, forward P/E of 16.82, and a debt-free balance sheet.
PG
NASDAQ · PGNY
Progyny, Inc.
Healthcare · Medical - Healthcare Information Services
$25.94
Down-$0.67 (-2.52%)
Updated Sep 6, 2026, 4:57 PM
SID Score
6.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.24B
- P/E ratio
- 42.01
- Dividend yield
- 0.00%
- 52-week range
- $16.10 – $33.07
- Volume
- 1.06M
- Avg. volume
- 1.58M
Price performance
PGNY price history
1M range · 20 trading sessions · Daily adjusted prices
PGNY closed at $25.94 after 20 trading sessions, down 6.86% for the selected period.
- Last close
- $25.94
- Period change
- -6.86%
- Period low
- $25.33
- Period high
- $27.85
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $26.51 | $26.665 | $25.82 | $25.94 | 1.06M |
| Sep 3, 2026 | $26.47 | $26.765 | $26.08 | $26.61 | 708.4K |
| Sep 2, 2026 | $25.71 | $26.63 | $25.71 | $26.29 | 1.03M |
| Sep 1, 2026 | $25.49 | $26.09 | $25.46 | $25.66 | 765.24K |
| Aug 31, 2026 | $25.98 | $26.101 | $25.47 | $25.59 | 911.93K |
| Aug 28, 2026 | $25.96 | $26.2599 | $25.89 | $26.00 | 832.67K |
| Aug 27, 2026 | $26.26 | $26.49 | $25.70 | $25.86 | 1.16M |
| Aug 26, 2026 | $25.60 | $26.47 | $25.60 | $26.37 | 1.12M |
| Aug 25, 2026 | $25.51 | $25.855 | $25.368 | $25.82 | 1.41M |
| Aug 24, 2026 | $25.65 | $25.895 | $25.34 | $25.45 | 815.36K |
| Aug 21, 2026 | $26.08 | $26.266 | $25.24 | $25.65 | 1.08M |
| Aug 20, 2026 | $26.14 | $26.59 | $25.805 | $25.96 | 1.14M |
| Aug 19, 2026 | $25.60 | $25.895 | $25.41 | $25.53 | 867.4K |
| Aug 18, 2026 | $25.63 | $26.01 | $25.57 | $25.71 | 995.7K |
| Aug 17, 2026 | $26.00 | $26.13 | $25.265 | $25.33 | 740.61K |
| Aug 14, 2026 | $25.76 | $26.46 | $25.72 | $26.28 | 850.49K |
| Aug 13, 2026 | $25.74 | $26.31 | $25.715 | $25.89 | 1.13M |
| Aug 12, 2026 | $26.27 | $26.311 | $25.39 | $25.42 | 1.48M |
| Aug 11, 2026 | $27.71 | $28.23 | $26.31 | $26.57 | 1.3M |
| Aug 10, 2026 | $27.85 | $28.87 | $27.735 | $27.85 | 1.27M |
Latest PGNY news
The latest Smart Investors Daily articles mentioning PGNY.
Stock researchCompany · Overview
PGNY research
Overview
Company profile and research snapshot.
Company profile
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $28.50
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 21, 2026 | JP Morgan | Neutral | — |
| Aug 20, 2026 | Wells Fargo | Overweight | — |
| Aug 13, 2026 | Truist Securities | Buy | — |
| Aug 12, 2026 | Barclays | Equal-Weight | — |
| Jul 28, 2026 | Barclays | Equal-Weight | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 21, 2026
JP Morgan Maintains Neutral on Progyny, Raises Price Target to $30
JP Morgan analyst Lisa Gill maintains Progyny (NASDAQ:PGNY) with a Neutral and raises the price target from $27 to $30.
Benzinga · Aug 20, 2026
Wells Fargo Initiates Coverage On Progyny with Overweight Rating, Announces Price Target of $37
Wells Fargo analyst Stan Berenshteyn initiates coverage on Progyny (NASDAQ:PGNY) with a Overweight rating and announces Price Target of $37.
ChartMill · Aug 20, 2026
Progyny (NASDAQ:PGNY): A Decent Value Stock Combining Reasonable Valuation and Solid Fundamentals
Progyny (PGNY) passes Decent Value screen: reasonable valuation, strong profitability, no debt, and solid growth. A quality value pick for investors.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
